Zymeworks Inc. is a Vancouver-based clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. Utilizing its proprietary platforms, Zymeworks has built a robust pipeline featuring antibody-drug conjugates and bispecific therapeutics, designed to meet significant unmet medical needs in oncology. The company's commitment to advancing targeted therapies, combined with strategic collaborations, positions it as a key contributor to the evolving biopharmaceutical sector, with the potential to deliver transformative solutions for patients suffering from various types of cancer. Show more
Location: 108 PATRIOT DRIVE, MIDDLETOWN, DE, UNITED STATES, 19709, Middletown, DE, 19709, USA | Website: https://www.zymeworks.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
1.716B
52 Wk Range
$9.03 - $28.49
Previous Close
$22.53
Open
$22.45
Volume
455,482
Day Range
$22.45 - $23.34
Enterprise Value
1.453B
Cash
64.83M
Avg Qtr Burn
-31.41M
Insider Ownership
0.98%
Institutional Own.
-
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Ziihera® (zanidatamab-hrii) Details Cancer, Solid tumor/s, Biliary Tract Cancer | Approved Quarterly sales | |
Zanidatamab + Chemo/trastuzumab Details Breast cancer, Cancer, HER2-expressing cancers | Approved Quarterly sales | |
Zanidatamab (HER2) + chemotherapy + tislelizumab Details Cancer, Gastroesophageal adenocarcinomas, Cholangiocarcinoma | Phase 3 Data readout | |
Pasritamig (Bispecific Antibody) Details Unspecified | Phase 3 Initiation | |
Zanidatamab zovodotin (ZW49) Details HER2-expressing cancers, Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Zanidatamab (HER2) + docetaxel Details Cancer, Breast cancer | Phase 1/2 Update | |
ZW171 Details Mesothelin-expressing solid tumors | Phase 1 Update | |
ZW191 Details Cancer, Solid tumor/s | Phase 1 Update | |
ZW251 (GPC3 ADC) Details Hepatocellular carcinoma (HCC) | Phase 1 Update | |
ZW327 (Antibody-Drug Conjugate) Details Cancer, Solid tumor/s | IND Submission | |
ZW418 (PTK7 ADC) Details Cancer, Solid tumor/s | IND Submission | |
ZW220 (NaPi2b ADC) Details Cancer | IND Submission |
